Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of TIVc vs TIV in At-Risk Children
NCT01998477Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Jul 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) in influenza, sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01998477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998477.